Zymeworks Inc.
Graphique
Bon à savoir : L’investissement en actions présente un potentiel de rendement à long terme, mais implique également un risque de perte, pouvant aller jusqu’à la totalité du capital investi. Les performances passées ne préjugent pas des performances futures. Les données fournies par des sources externes n’ont pas été modifiées par Saxo. Voir la clause de non-responsabilité
À propos Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
/ 